Phosphatidylethanol vs Transdermal Alcohol Monitoring for Detecting Alcohol Consumption Among Adults
- PMID: 37698861
- PMCID: PMC10498325
- DOI: 10.1001/jamanetworkopen.2023.33182
Phosphatidylethanol vs Transdermal Alcohol Monitoring for Detecting Alcohol Consumption Among Adults
Abstract
Importance: Alcohol biomarkers can improve detection of heavy alcohol use in clinical care, yet cutoffs for phosphatidylethanol (PEth), a blood biomarker, have not been established.
Objective: To determine the optimal cutoff for PEth for heavy alcohol consumption in a study of middle-age and older adults.
Design, setting, and participants: This was a 4-week diagnostic study of adults with paroxysmal atrial fibrillation (AF) and current alcohol consumption, recruited from general cardiology and cardiac electrophysiology outpatient clinics from September 2014 to September 2019. Data were analyzed from October 2021 to March 2022.
Main outcomes and measures: The main aim was to determine the optimal PEth cutoff for heavy alcohol consumption, using the Secure Continuous Remote Alcohol Monitor (SCRAM) to measure transdermal alcohol. Area under the curve (AUC) for PEth-detected compared with SCRAM-detected heavy alcohol consumption in any week over the prior 4 weeks (ie, ≥3 [women] and ≥4 [men] episodes) or any estimated breath alcohol of 0.08% or greater in any week, and the PEth cutoff was calculated using the Youden J statistic. Similar analyses were conducted comparing PEth with individual drinks reported by pressing an event monitor, retrospective self-report via the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), and using 2-week look-backs.
Results: In this diagnostic study of 64 patients with both PEth and SCRAM measures over 4 weeks (54 [84.4%] men; mean age, 65.5 [95% CI, 62.6-68.5] years; 51 [79.7%] White), 31 (48.4%) had any SCRAM-detected heavy alcohol consumption over the 4 weeks, and the median (IQR) PEth at 4 weeks was 23 ng/mL (<limit of quantification to 60 ng/mL). The AUC for PEth vs any SCRAM-detected heavy alcohol consumption was 0.83 (95% CI, 0.72-0.93). The optimal PEth cutoff was 18.5 ng/mL (AUC, 0.83; 95% CI, 0.72-0.93), with sensitivity of 83.9% (95% CI, 66.3%-94.5%) and specificity of 72.7% (95% CI, 54.5%-86.7%). The PEth test characteristics by individual drink reporting using the event monitors and by the AUDIT-C, and by these measures and by SCRAM collected for 2-week intervals, were similar to those compared with the 4-week SCRAM.
Conclusions and relevance: In a predominately middle-age and older White male population, PEth compared well with SCRAM. A PEth cutoff of 18.5 ng/mL (or rounded to 20 ng/mL, a recommended PEth cutoff for significant alcohol consumption) can be used in clinical care to detect heavy alcohol consumption in middle-age and older men.
Conflict of interest statement
Figures
Similar articles
-
Correlates of high phosphatidylethanol (PEth) levels and their concordance with self-reported heavy alcohol consumption among men who have sex with men who binge drink alcohol.Alcohol Clin Exp Res. 2022 Aug;46(8):1565-1579. doi: 10.1111/acer.14891. Epub 2022 Jul 8. Alcohol Clin Exp Res. 2022. PMID: 35722862 Free PMC article. Clinical Trial.
-
Relationship of Phosphatidylethanol Biomarker to Self-Reported Alcohol Drinking Patterns in Older and Middle-Age Adults.Alcohol Clin Exp Res. 2020 Dec;44(12):2449-2456. doi: 10.1111/acer.14475. Epub 2020 Nov 9. Alcohol Clin Exp Res. 2020. PMID: 33038267 Free PMC article.
-
Validating Self-Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV.Alcohol Clin Exp Res. 2020 Oct;44(10):2053-2063. doi: 10.1111/acer.14435. Epub 2020 Sep 19. Alcohol Clin Exp Res. 2020. PMID: 33460225 Free PMC article.
-
Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights.Int J Mol Sci. 2023 Jul 29;24(15):12175. doi: 10.3390/ijms241512175. Int J Mol Sci. 2023. PMID: 37569551 Free PMC article. Review.
-
Phosphatidylethanol in blood (B-PEth): a marker for alcohol use and abuse.Drug Test Anal. 2011 Apr;3(4):195-200. doi: 10.1002/dta.278. Epub 2011 Mar 25. Drug Test Anal. 2011. PMID: 21438164 Review.
Cited by
-
Diagnosis of Alcohol Use Disorder and Alcohol-Associated Liver Disease.Clin Liver Dis. 2024 Nov;28(4):699-713. doi: 10.1016/j.cld.2024.06.009. Epub 2024 Aug 13. Clin Liver Dis. 2024. PMID: 39362716 Review.
-
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.Hepatol Int. 2024 Oct;18(Suppl 2):897-908. doi: 10.1007/s12072-024-10699-x. Epub 2024 Aug 8. Hepatol Int. 2024. PMID: 39115632 Review.
References
-
- National Institute of Alcohol Abuse and Alcoholism. Drinking levels defined. Accessed July 1, 2016. https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/mo...
-
- Curry SJ, Krist AH, Owens DK, et al. ; US Preventive Services Task Force . Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(18):1899-1909. doi:10.1001/jama.2018.16789 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
